You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a Tritiated Agonist Radioligand for the D2 Receptor

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: OD

    DESCRIPTION (provided by applicant): The goal of this project is to develop a novel agonist radioligand for evaluating the proportion of D2 receptors in the high state. The D2high receptor is thought to be the functional form of the D2 receptor to which endogenous dopamine binds. An agonist radioligand should be more sensitive to endogenous DA levels than antagonist radioligands since, unlike anta ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Development of cGMP Manufacturing Process for CBD

    SBC: APHIOS CORPORATION            Topic: NIDA

    DESCRIPTION (provided by applicant): Medical marijuana is now approved in 20 states and the District of Columbia for several medical conditions such as cachexia, cancer, chronic pain, epilepsy and other disorders characterized by seizures, glaucoma, HIV, AIDS, Multiple Sclerosis, muscle spasticity and nausea. Progress has been made on several fronts on the use of cannabinoids for medical use such ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Gap Junction Inhibition Therapy for Alcoholic Liver Disease

    SBC: HEPROTECH, INC.            Topic: NIAAA

    ? DESCRIPTION (provided by applicant): Alcoholic liver disease is a highly prevalent and costly condition affecting millions of people globally. Alcohol results in high morbidity and mortality an is responsible for nearly 4% of all deaths worldwide. Despite the tremendous societal and economic burden, there is no approved therapeutics for alcoholic liver disease. Instead, the standard of care ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Oxymorphone DETERx, an abuse-deterrent, extended-release opioid fo

    SBC: COLLEGIUM PHARMACEUTICAL, INC.            Topic: NIDA

    DESCRIPTION: The overall objective of the research is to further the development of an abuse-deterrent formulation of the potent opioid analgesic oxymorphone utilizing the DETERx(R) platform technology. The DETERx technology is a patented formulation approach to abuse-deterrence that establishes physical and chemical barriers designed to avoid dose dumping when the formulation is subjected to a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NIDDK

    DESCRIPTION provided by applicant Non alcoholic steatohepatitis NASH is characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosis and cirrhosis and high mortality rates NASH is frequently associated with other common metabolic abnormalities such as insulin resistance and visceral obesity Liver transplantation is curren ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Praedicare Dx as CDx for AML Period of Performance: September 19, 2014 through September 18, 2015

    SBC: Eutropics Pharmaceuticals, Inc.            Topic: DCCPS

    Not Available

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of SFS Fractionators

    SBC: APHIOS CORPORATION            Topic: NCCIH

    DESCRIPTION (provided by applicant): The screening of a complex mixture of analytes is not always successful in sensitive screens for specific activities. Often, specific activities are masked by interfering compounds or false positives are given by ubiquitous compounds that interact with all screens. This problem can be resolved by purification of the analytes. Such an approach is not only cost-p ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of small near-infrared laser system capable of improving immune respo

    SBC: SEMINEX CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): The broad and long-term objective of this project is to amplify the effectiveness of vaccines without the use of chemical or biological adjuvants. We will address this objective by demonstrating the feasibility for small laser- based devices to enhance responses to intradermal vaccination. A number of investigators have shown that a promising new way to make va ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Development of SVAD System for HF Therapy

    SBC: SCR, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): The objective of this proposal is to complete the engineering development and pre-clinical testing of the SCR SVAD system to provide partial cardiac assist in patients with less advanced stage heart failure (HF). HF isincreasing worldwide and represents a major burden in terms of health care resources and costs. Despite advances in medical care, prognosis with ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Development of TransApical to Aorta Double Lumen Cannula for a Neonate LVAD

    SBC: W-Z BIOTECH LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Left ventricular assist device (LVAD) support allows the neonate with congenital heart disease or cardiomyopathy to grow to a larger body weight that is more feasible for complex surgical correction or heart transplant.A paracorporeal LVAD, the Berlin heart ExCor, is FDA-approved for pediatric application. Although this device is outside the body, the outflow g ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government